According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
8
Feb, 2021
Elizabeth PaynePublishing date:Feb 04, 2021 Fewer Canadians have been diagnosed with cancer during the COVID-19 pandemic compared with previous years. Far from being something to celebrate, it is part of a global trend that is raising alarm bells. Across…
READ MORE
4
Feb, 2021
World Cancer Day every 4 February is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalysing personal, collective and government action, we're working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equal for all - no matter who you are or where you live. Created in 2000, World Cancer Day has grown into…
READ MOREMarch 2, 2021
Vancouver, British Columbia – (March 2, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has granted 2,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two years from the date of grant. All other terms and conditions of […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.